Clinical trials evolve: Agile, data-driven, patient-centric.

Amelia Thompson*

Department of Clinical Medicine, St. George Medical College, University of Edinburgh, Edinburgh, UK

Introduction

Modern clinical trials are rapidly evolving for efficiency and patient-focus. Adaptive designs are crucial, especially during emergencies. They allow dynamic adjustments based on accumulating data, making research flexible and efficient. This accelerates treatment evaluation, providing faster answers and better use of patient data while maintaining rigor, transforming traditional trials [1].

Real-world evidence (RWE) is vital for regulatory decisions. It uses routine clinical practice data, like electronic health records, to understand treatment effectiveness and safety outside controlled trials. RWE complements randomized trials, offering a fuller picture of interventions in diverse patient populations under everyday conditions, broadening drug utility perspectives [2].

Integrating patient-reported outcomes (PROs) into oncology trials is essential for capturing patient perspective on treatment effects, including symptoms and quality of life. While data collection presents challenges, PROs offer a holistic assessment of treatment benefit. This moves beyond clinical endpoints to understand true daily life impact, critical for patient-centered care [3].

Decentralized clinical trials (DCTs) transform research by shifting activities from sites to participants' homes via technology. This model improves patient access, engagement, and retention, reducing burden. It also broadens study geographic reach and accelerates timelines. Hybrid models combining centralized and decentralized elements are also emerging for optimal efficiency [4].

Ethical considerations during public health emergencies are paramount. Rapidly developing interventions under urgent circumstances raises complex questions about informed consent, equitable access, and data privacy. Balancing speed with protecting participants and maintaining public trust is key. Clear ethical frameworks are vital for navigating these challenging situations effectively [5].

Biomarkers play a critical role in oncology trials, moving from prognosis to guiding precision medicine. These indicators identify patients most likely to respond, stratify groups, and monitor efficacy. Using biomarkers means tailoring treatments, reducing trial sizes, accelerating development, and getting the right drug to the right patient faster. It's a game-changer for personalized cancer care [6].

Artificial Intelligence (AI) rapidly transforms clinical trials, offering solutions across research stages. AI can optimize trial design, identify suitable patients, monitor adverse events, and analyze complex datasets efficiently. This means faster drug discovery, more accurate predictions, and reduced burden on researchers. AI holds immense promise for making studies smarter and more productive [7].

Data sharing in clinical trials is crucial for advancing scientific discovery and maximizing research value, but it brings challenges, especially regarding participant perspectives. Researchers see benefits in reproducibility, yet participants often concern themselves with privacy and data usage. Building trust and transparently communicating benefits and risks is key to fostering open science practices [8].

Master protocols represent a modern, efficient approach to drug development, particularly in oncology. Instead of separate trials for each drug-disease combination, a master protocol allows umbrella trials (multiple drugs in one disease), basket trials (one drug in multiple diseases), or platform trials (continuous evaluation). This streamlines research, shares infrastructure, and speeds up identifying effective treatments [9].

Biomarker-driven clinical trials are fundamental to advancing personalized medicine in oncology. They use specific molecular characteristics in a patient's tumor to guide treatment, matching therapy to the right patient. This strategy helps avoid ineffective treatments, reduces side effects, and focuses resources on therapies more likely to succeed. It's a targeted approach aiming to improve outcomes [10].

Conclusion

Clinical trials are evolving rapidly, driven by innovations in design, data utilization, and technology to enhance efficiency and patient-centricity. New approaches include adaptive trial designs, which allow for flexible adjustments based on accumulating data, and master

***Correspondence to:** Amelia Thompson, Department of Clinical Medicine, St. George Medical College, University of Edinburgh, Edinburgh, UK. E-mail: amelia.thompson@stgmed.ed.ac.uk

Citation: Thompson A. Clinical trials evolve: Agile, data-driven, patient-centric. aaajmr. 2025;09(03):291.

protocols like umbrella, basket, and platform trials that streamline drug development, particularly in oncology. Decentralized trials, leveraging technology for remote participation, are improving patient access and accelerating timelines.

The integration of diverse data sources is also pivotal. Real-world evidence now complements traditional randomized trials, offering broader insights into treatment effectiveness and safety in everyday settings for regulatory decisions. Biomarkers are becoming critical, not just for prognosis but for guiding precision medicine in oncology, enabling tailored treatments. Artificial Intelligence is transforming various trial stages, from optimizing design to analyzing complex data, promising faster drug discovery and more accurate predictions.

However, these advancements come with important considerations. Patient-reported outcomes are increasingly integrated to capture the patient's holistic experience, moving beyond clinical endpoints. Ethical considerations, especially during public health emergencies, remain paramount, focusing on informed consent, equitable access, and data privacy. Data sharing, while crucial for scientific progress, requires careful management of participant privacy concerns. These interconnected trends are shaping a future where clinical research is more agile, insightful, and responsive to patient needs.

References

1. Sung H K, Jin H P, Young M K. Adaptive Clinical Trial Designs for COVID-19: *A Review. J Clin Transl Sci.* 2021;5(1):e16.

2. Robert G F, Chang K G, Amber M J. Generating Real-World Evidence to Support Regulatory Decisions: *A Review of Methodological Considerations. Pharmaceut Med.* 2022;36(1):21-34.

3. Taru S K, Kavita S A, Robert M D. Integrating Patient-Reported Outcomes in Oncology Clinical Trials: *Challenges and Opportunities. Curr Oncol Rep.* 2023;25(5):493-502.

4. Tarun K S, Vikas K S, Ajay P G. Decentralized Clinical Trials: Current Landscape, Challenges, and *Future Directions. Clin Pharmacol Ther.* 2022;111(5):959-968.

5. Laura M B, Lisa M E, *Ellen K M G. Ethical Considerations in Clinical Research During a Public Health Emergency. J Empir Res Hum Res Ethics.* 2021;16(1-2):47-59.

6. Nikolaos G K, Athanasios K K, Evangelos N V. The Role of Biomarkers in Oncology Clinical Trials: *From Prognosis to Precision Medicine. Cancers* (Basel). 2023;15(3):853.

7. Yu Z, Qian W, Ming L. Artificial intelligence in clinical trials: current applications and future perspectives. *BMC Med.* 2024;22(1):31.

8. Eun H L, Michael H C, Sung L L. Data sharing in clinical trials: a view from participants. *J Med Ethics.* 2020;46(4):255-260.

9. Jae S K, Min C L, Hyun J K. Master Protocols: *A Modern Approach to Drug Development. Clin Cancer Res.* 2021;27(1):14-23.

10. Bruce E J, Jennifer A K, Lauren M S. Biomarker-Driven *Clinical Trials for Personalized Medicine in Oncology. JAMA Oncol.* 2020;6(7):1098-1105.